Table 7 Economic impact of observed comorbidities (mean total cost) among the populations with one comorbidity. (average cost excluding the related HCV therapy costs)
HIV+ Mono-infected patients N = 251 | HIV/HCV Co-infected patients N = 200 | Delta between HIV/HCV and HIV+ patients [%] | p-value between HIV/HCV and HIV+ patients | |
|---|---|---|---|---|
Cardiovascular comorbidities | € 10,116.58 | € 20,724.95 € 11,004.28* | 51.19% 8.07%* | 0.001 > 0.050* |
Neurocognitive impairments | € 7,706.43 | € 11,641.29 € 11,641.29* | 33.80% 33.80%* | < 0.001 < 0.001* |
HBV infection | € 9,551.84 | € 28,790.25 € 13,230.36* | 66.82% 27.80%* | > 0.050 > 0.050* |
Bone events | € 8,953.19 | € 12,097.29 € 10,972.37* | 25.99% 18.40%* | > 0.050 > 0.050* |
Renal impairments | € 9,162.64 | € 8038.49 € 8038.49* | −13.98% − 13.98%* | > 0.050 > 0.050* |
Diabetes | € 10,249.13 | € 26,723.49 € 11,541.70* | 61.65% 10.99%* | > 0.050 > 0.050* |
One-way ANOVA | 0.215 | 0.017 |